Tag

AbbVie

9 stories

Deals Jul 6, 2026

Novartis Buys Myricx for $1.1B in ADC Push

Novartis just paid $1.1B for a biotech whose lead drugs have never touched a human patient. The math on that bet doesn't look cheap.

Deals Jun 22, 2026

Nuvectis Buys Haisco Factor B Rights for $40M

Nuvectis paid $40M upfront for ex-China rights to Haisco's once-daily Factor B inhibitor in a PNH market projected above $5B in 2026.

Deals Apr 17, 2026

Daiichi Sankyo Sold $1.55B Consumer Unit to Suntory

Daiichi Sankyo will sell its consumer health subsidiary to Suntory Holdings for 246.5 billion yen, about $1.55 billion, paid in tranches over three years.

FDA Apr 13, 2026

Beats Venetoclax: Lilly's Jaypirca Posts 4th Phase 3 Win in CLL

Jaypirca chalked up its fourth positive phase 3 readout in chronic lymphocytic leukemia on Monday, and this one rewrites the treatment calculus: it's the…

Deals Apr 13, 2026

AbbVie Bought Two NaV1.8 Pain Assets from Haisco for $745M

AbbVie bought ex-China rights to two NaV1.8 sodium channel pain inhibitors from Beijing-based Haisco Pharmaceutical for up to $745 million.

Deals Apr 13, 2026

Kailera Files $528.5M Nasdaq IPO to Fund Four GLP-1 Obesity Drugs

Kailera filed for a $528.5 million Nasdaq IPO, pricing 33.33 million shares at $14 to $16 each.

FDA Apr 8, 2026

Lilly Foundayo Clears FDA; Novo's Oral Holds 5-Point Lead

Lilly's oral obesity pill approved but trails Novo on weight loss. Pharma's M&A sprint added $7.9B in deals and Trump's tariffs landed with carveouts.

FDA Apr 7, 2026

TrumpRx Lists AbbVie's Humira at $950/Month Next to Cheaper Biosimilars

White House added Humira to TrumpRx at $950/month, the same site that already lists cheaper Pfizer and Amgen biosimilars.

Deals Apr 6, 2026

Anthropic Pays $400M for a 10-Person Ghost Company

Anthropic is paying ~$400M for Coefficient Bio, a sub-10-person stealth startup. The price signals how expensive life sciences AI talent has become.